New York University
New York, 10003, United States
NCT Number: NCT05456100
The Chinese American Cancer Survivors Writing Study is a Randomized Controlled Trial (RCT) testing the feasibility and efficacy of the Expressive Helping (EH) intervention among Chinese American cancer survivors.
This study is active but is not currently recruiting participants.
Notify MeChinese Americans are one of the fastest growing immigrant groups in the United States, but there is still a lack of culturally-sensitive and linguistically-appropriate resources and interventions for this group. To address this gap, the investigators will examine the efficacy and feasibility of Expressive Helping, a writing intervention designed to lead participants to write about their cancer experiences. Participants will be adult cancer survivors of Chinese descent. After screening and consent, eligible participants will be enrolled in a 1:1:1 randomized controlled trial. Assessments of psychological symptoms will occur at baseline (prior to randomization), 1-month post-intervention, 3-months post-intervention, and 6-months post-intervention.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Expressive helping involves a combination of emotional disclosure and peer support writing completed over four weeks.
Expressive writing involves emotional disclosure writing over four weeks.
Factual writing involves writing facts about cancer treatment and experiences over four weeks.
Time frame: through study completion, an average of 6 months
The number of participants screened for eligibility, percent eligible to participate, and percent of people who refuse to participate will be tracked.
Time frame: through study completion, an average of 6 months
Percent of participants who complete each stage of the study (e.g., baseline survey, writing sessions, follow-ups) will be tracked.
Time frame: through study completion, an average of 6 months
Assessed by dividing the number of writing sessions finished by the number of sessions assigned.
Time frame: Baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up
Depressive symptoms will be measured with the 10-item Center for Epidemiologic Studies Depression Scale (CES-D). The score can range from 0-30 and higher scores indicate more depressive symptoms.
Time frame: Baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up
Anxiety symptoms will be measured with the 7-item GAD-7 scale (Spitzer et al., 2006). This scale measures generalized anxiety symptoms in the past 7 days, has score ranges from 0-21 with higher scores indicating greater anxiety symptoms.
Time frame: Baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up
Health-related quality of life will be measured by the 27-item FACT-G, which assess four domains: physical well-being, social well-being, emotional well-being and functional well-being. The score ranges from 0-108 with higher scores indicating better quality of life.
Time frame: Baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up
Perceived stress is measured by the 10-item Perceived Stress Scale (PSS). The score ranges from 0-40 with higher scores indicating higher perceived stress.
Time frame: Baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up
Cancer-related fatigue is measured by the 13-item Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT). The score ranges from 0-52 with higher scores indicating greater fatigue.
New York University
Other
A Randomized Controlled Trial Testing Expressive Helping for Chinese American Cancer Survivors
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06192758
Cancer, Chromosome 2q32-Q33 Deletion Syndrome
Chicago, Illinois, United States
View Trial DetailsNCT01169259
Cancer, Cardiovascular Disease
Boston, Massachusetts, United States
View Trial DetailsNCT07076004
Cancer, Neoplasms
New Haven, Connecticut, United States
View Trial DetailsNCT00339495
Cancer, Death
Rockville, Maryland, United States
View Trial Details